Nonalcoholic Fatty Liver Disease
Conditions
Keywords
nonalcoholic fatty liver disease, Pulse wave velocity, augmentation index, metformin
Brief summary
Abstract Background: Insulin resistance has an important role in the development of nonalcoholic fatty liver disease (NAFLD) and is involved in both pathological processes: hepatic steatosis and atherosclerosis. Therefore, treatment of NAFLD with insulin sensitizers is likely to have a favorable effect towards hepatic steatosis and cardiovascular outcomes. Objectives: The present study investigated the effect of metformin on arterial properties, metabolic parameters and liver function in patients with NAFLD. Methods In randomized, placebo controlled study, 63 patients with NAFLD were assigned to one of two groups: Group 1 received daily metformin; Group 2 received placebo. Pulse wave velocity (PWV) and augmentation index (AI) were performed using SphygmoCor (version 7.1, AtCor Medical, Sydney, Australia) at baseline and at the end of 4-month treatment period.. Metabolic measures and serum adiponectin levels were determined.
Interventions
DRUGMetformin
Sponsors
Wolfson Medical Center
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* In a single-center study, 63 patients (32 males and 31 females) diagnosed with nonalcoholic fatty liver disease were recruited from the outpatient clinic and evaluated for the study.
Exclusion criteria
* Patients with history of unstable angina, MI, CVA or major surgery within the six months preceding entrance to the study. * Patients with unbalanced endocrine disease or any disease that might affect absorption of medications. * Patients with plasma creatinine \> 1.5 mg/dl, and electrolyte abnormalities.
Countries
Israel
Outcome results
None listed